



Taichi Nakamura

Dr. Taichi Nakamura graduated from Kyushu University faculty of Medicine in 2002 and acquired a doctor's license in Japan. He has conducted medical training at Kyushu University Hospital, Beppu Medical Center, and Kyushu Cancer Center, and acquired knowledge, skills and experience on internal medicine, gastroenterology and pancreatic pathology. From 2007, while continuing clinical practice, he entered the Graduate School of Kyushu University, where he studied basic science focusing on the effects of bacteria and virus nucleic acid ligands as well as the effects of lipid ligands, alcohol metabolites, TRPV1 ligands on pancreatic diseases by using pancreatic stellate cells *in vitro* and using animal disease models *in vivo*. Since 2012 he has been engaged in Molecular Pharmacology research as a visiting researcher at the National Institutes of Health in the United States and has studied the receptor-ligand structure correlation using an orphan receptor, BRS-3, and its synthetic peptide and non-peptide ligands, and clarified its important structure factors contributing to its affinity and selectivity. He joined GlaxoSmithKline Japan in 2015 and played a role for monitoring data and evaluating relationships between drugs and adverse events from a medical point of view for individual cases and accumulated cases in the safety department. He also played a project leader for developing an autoscoring system to screen a large amount of text documents according to their drug-adverse events relationships using a Semantic text-mining tool. Since 2018 he has transferred to ViiV Healthcare Company, a company dedicated to support for patients living with HIV, holding Advisory board meetings, building a good scientific engagement, and promoting data generation as a medical manager.